Maravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) was the target of unusually large options trading activity on Wednesday. Traders acquired 1,002 put options on the company. This is an increase of 1,791% compared to the average daily volume of 53 put options.

Institutional Trading of Maravai LifeSciences

A number of large investors have recently added to or reduced their stakes in the company. Wedmont Private Capital lifted its stake in Maravai LifeSciences by 14.1% in the first quarter. Wedmont Private Capital now owns 42,439 shares of the company’s stock valued at $361,000 after acquiring an additional 5,242 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in shares of Maravai LifeSciences in the first quarter valued at about $187,000. Virtu Financial LLC bought a new position in shares of Maravai LifeSciences in the fourth quarter valued at about $136,000. GSA Capital Partners LLP bought a new position in shares of Maravai LifeSciences in the fourth quarter valued at about $320,000. Finally, Voloridge Investment Management LLC bought a new position in shares of Maravai LifeSciences in the fourth quarter valued at about $2,571,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Analyst Upgrades and Downgrades

MRVI has been the subject of several recent analyst reports. Craig Hallum initiated coverage on shares of Maravai LifeSciences in a research note on Wednesday, April 10th. They issued a “buy” rating and a $15.00 target price for the company. Royal Bank of Canada upped their target price on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, February 23rd. Finally, Stifel Nicolaus reduced their price target on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.56.

Maravai LifeSciences Stock Performance

Shares of MRVI opened at $7.73 on Thursday. Maravai LifeSciences has a 12 month low of $4.52 and a 12 month high of $16.62. The firm has a fifty day simple moving average of $7.48 and a 200 day simple moving average of $6.76. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -8.59 and a beta of 0.01. The company has a current ratio of 8.00, a quick ratio of 7.41 and a debt-to-equity ratio of 0.70.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). The firm had revenue of $74.14 million during the quarter, compared to analyst estimates of $62.99 million. Maravai LifeSciences had a negative net margin of 41.19% and a negative return on equity of 1.31%. Research analysts forecast that Maravai LifeSciences will post -0.15 EPS for the current fiscal year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.